Scholar Rock (NASDAQ: SRRK) is Breaking Out and is Now Setting Up for 31% Upside

Scholar Rock Holding Corporation (NASDAQ: SRRK) is breaking out of a multi-month ascending triangle and looks headed even higher.

As we’ll get to just ahead, the combination of an FDA-accepted apitegromab BLA with a September 30 PDUFA date, accelerating U.S. and European commercial launch readiness, and a fresh technical breakout makes SRRK one of the more interesting setups on the board. Here’s what’s going on…

The Themes Behind the Move

Scholar Rock is a late-stage biotech developing monoclonal antibodies that selectively target precursor forms of growth factors in the TGFβ superfamily. Its lead asset is apitegromab — a muscle-targeted myostatin inhibitor in development for spinal muscular atrophy (SMA), with additional pipeline programs in facioscapulohumeral muscular dystrophy (FSHD), solid tumors, fibrotic diseases, and iron-restricted anemias.

In plain English, apitegromab doesn’t replace existing SMA treatments like Biogen’s Spinraza or Novartis’s Zolgensma — it works alongside them by helping preserve and build the muscle that disease-modifying SMN therapies can’t directly address. That means Scholar Rock’s near-term story hinges on three things: getting apitegromab over the FDA finish line, executing the U.S. and European commercial launch cleanly, and continuing to advance the broader pipeline behind it.

SRRK’s latest move reflects a powerful confluence of developments — clinical, regulatory, and commercial — that have come together in rapid succession to fundamentally de-risk the apitegromab launch and reframe the company’s near-term growth trajectory.

If needed, swipe or scroll sideways to view the full table.

Put it all together, and SRRK is looking less like a speculative pre-commercial biotech and more like a commercially-ready rare-disease franchise with a de-risked BLA, dual-site manufacturing, a fortified balance sheet, and Wall Street’s most respected biotech desk publicly anchoring expectations to the upside.

The story is getting stronger by the week, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.

Bullish Technical Signals

#1 Ascending Triangle Pattern: The daily chart reveals a well-defined ascending triangle — a classically bullish continuation pattern marked in purple. Price is compressing against flat resistance while printing progressively higher lows, reflecting buyers willing to pay up at each pullback. A decisive breakout above the triangle’s horizontal resistance would confirm the pattern and unlock measured-move upside roughly equal to the triangle’s height. Post-breakout, the rising trendline base typically converts into dynamic support, offering a natural reference point for risk management.

SRRK – Daily Chart

#2 Price above MAs: SRRK is trading above both its 50-day and 200-day simple moving averages — a dual confirmation that the intermediate- and long-term trends are aligned to the upside. This “stacked” MA structure (price > 50-SMA > 200-SMA) is one of the clearest signals that bulls hold structural control. Both averages now serve as layered dynamic support zones, meaning any pullback into them is more likely to attract buyers than signal a reversal.

#3 Bullish Aroon: The Aroon oscillator on the daily chart paints a textbook bullish picture: Aroon Up (orange) is pinned above 70 while Aroon Down (blue) languishes below 30. This spread tells us two things simultaneously — the stock is consistently printing new highs within its lookback window, and it has gone an extended period without registering new lows. In short, buyers are active and sellers are absent, the hallmark of a trend with room to run.

#4 Bullish ADX: The ADX indicator adds a critical momentum layer. The +DI line sits firmly above the –DI line, confirming buyers are dictating trend direction. More telling is the ADX line itself: it’s rising from a low base toward the +DI — a configuration that signals a trend not just present but actively gaining strength. When ADX climbs out of sub-20 territory while +DI leads, it historically correlates with the early acceleration phase of a sustainable move, not the late innings of an exhausted one.

#5 Holding Above Support: Zooming out to the weekly chart, SRRK has reclaimed a key horizontal level (marked by the pink dotted line near $45.13) that previously acted as stubborn resistance. That former ceiling now functions as a floor — a classic polarity flip that tends to be one of the most reliable support structures in technical analysis. With price also trading above the 50-week and 200-week SMAs, the longer-term trend architecture remains firmly bullish and structurally intact.

SRRK – Weekly Chart

#6 %K above %D: On the weekly chart, the %K line has crossed above the %D line — a momentum crossover that signals buying pressure is overtaking selling exhaustion. This crossover gains added weight because it occurred after a pullback within an established uptrend, rather than from deeply oversold territory, suggesting the broader trend is reasserting itself rather than staging a mere relief bounce. It points to a favorable window for longer-term accumulation.

#7 Bullish RSI: The weekly RSI sits above the 50 midline and is trending higher — a two-part bullish read. Holding above 50 confirms that buying momentum structurally outweighs selling pressure on a weekly closing basis. The continued upward slope rules out a stalling or plateauing signal; instead it indicates momentum is actively building, consistent with the early-to-mid stages of a durable uptrend rather than a late-cycle blow-off.

Risks to Consider

Even strong setups can fail, especially in a pre-commercial biotech name like Scholar Rock. A few things could knock the stock off course:

• A breakdown back below the ascending triangle’s rising trendline base on heavy volume
• Negative company-specific news or broader market weakness that pressures biotech and specialty pharma names
• Regulatory or label-related risk around the September 30, 2026 apitegromab PDUFA decision — any delay, restrictive label, or surprise post-marketing requirement could materially dent the launch thesis
• Manufacturing risk — while the dual-facility strategy has reduced exposure, any new FDA observations during the Catalent reinspection could still stall commercial supply
• Insider selling — over the past three months, the CEO, COO, CFO, and President of R&D have all made substantial sales (net -$3.15 million), with zero reported insider purchases; this can dampen sentiment even when tied to scheduled 10b5-1 plans
• Continued unprofitability and first-launch execution risk — SRRK is pre-revenue, and SMA is an established but competitive market against entrenched players like Biogen’s Spinraza and Novartis’s Zolgensma
• Competition from existing SMN-targeted therapies that dominate the SMA standard of care, plus emerging neuromuscular candidates that could erode the add-on positioning over time
• General biotech volatility — clinical-stage-to-commercial transitions remain inherently binary, and broader macro headwinds (rates, policy) can amplify drawdowns in speculative names

The Bottom Line

SRRK is breaking out of a multi-month ascending triangle on the daily chart while holding firmly above a resistance-turned-support level on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.

The fundamental story underneath the chart is just as strong: an FDA-accepted apitegromab BLA with a September 30 PDUFA date, dual-site U.S. manufacturing plus a queued European launch in Germany, and a JPMorgan “Positive Catalyst Watch” backed by ~91% institutional ownership — a rare tape signal that the smart money is already positioned ahead of the binary event.

Combine that with multiple regulatory and commercial catalysts staggered through year-end — PDUFA, the EMA CHMP opinion, the German launch, FORGE trial initiation, and Q2 earnings — and SRRK looks like one of the more compelling risk-reward setups on the board right now.

If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our exact entry level, both price targets that imply 20%–31% potential upside, and the stop-loss we’re using to manage the downside.

Recommended Trade Setup

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $5.50 per share, the target rewards are about $10.00 and $16.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Note on Trade Invalidation: This recommendation remains active only as long as the underlying technical structure is intact. If SRRK declines to or below the $46.50 stop-loss before the $52.00 buy level triggers, the trade is automatically void — a breach of that level would compromise the support architecture (including the ascending triangle base and the resistance-turned-support zone near $45.13) that underpins the entire thesis, meaning the setup no longer offers a favorable risk-reward entry.

Happy Trading!
Tara and Greg